High Q and Galadeno, Galapagos' partnering unit, will use Galapagos' adenoviral siRNA and cDNA collections to discover and validate drug targets for the development of new
Galapagos said that it could ultimately receive up to $3 million from the High Q Foundation for the project. The company also has the option to develop certain targets identified in the program.
Galapagos said that the final agreement with High Q has not yet been signed, but that it expects to do so before Oct. 1.
The company signed a similar agreement with the Cystic Fibrosis Foundation in April.